ACI-24疫苗在唐氏综合征成人中的安全性、耐受性和免疫原性:一项1b期随机临床试验
这项在美国3个学术医学中心开展的多中心双盲安慰剂对照剂量递增1b期随机临床试验,纳入16名25至45岁唐氏综合征成人,按3:1随机接受ACI-24疫苗300μg或1000μg或安慰剂共7次皮下注射。结果显示无脑膜脑炎、死亡或其他严重不良事件,大多数治疗中出现的不良事件为轻度且与疫苗无关或不太可能相关,12名接种者中4名(33.3%)出现抗Aβ免疫球蛋白G滴度升高而安慰剂组为0名。作者认为结果支持在唐氏综合征个体中使用优化配方的ACI-24疫苗推进临床试验。
要点
- ACI-24疫苗在唐氏综合征成人中安全且耐受良好,无脑膜脑炎、死亡或其他严重不良事件。
- 12名接种者中4名(33.3%)抗Aβ免疫球蛋白G滴度升高,安慰剂组0名。
- 作者认为结果支持使用优化配方的ACI-24疫苗在唐氏综合征个体中推进临床试验。
核心结论
- 在本研究中,ACI-24疫苗在唐氏综合征成人中安全且耐受良好。
- 观察到免疫原性证据以及药效动力学和靶点结合证据,抗Aβ抗体滴度与任何不良发现无关。
- 这些结果支持在唐氏综合征个体中使用优化配方的ACI-24疫苗推进临床试验。
研究设计与样本
- 多中心双盲安慰剂对照剂量递增1b期随机临床试验,在美国3个学术医学中心附属唐氏综合征门诊开展,时间为2016年3月30日至2020年6月29日。
- 筛查20名唐氏综合征成人,其中16名符合条件入组;纳入标准为25至45岁、经细胞遗传学诊断为21三体或21号染色体完全不平衡易位的男性或女性。
- 2016年4月27日至2018年7月2日期间,参与者按3:1随机分入2个剂量水平队列(每队列8名,6名接受ACI-24疫苗、2名接受安慰剂),研究为期96周。
- 参与者接受48周治疗,随后额外48周安全性随访。
- 参与者随机接受7次皮下注射ACI-24 300μg或1000μg或安慰剂。
主要发现
- 16名入组参与者平均(SD)年龄为32.6(4.4)岁;9名为女性,7名为男性;所有参与者均为白人,1名参与者为西班牙裔或拉丁裔。
- 治疗依从性为100%;无脑膜脑炎、死亡或其他严重不良事件病例,无因不良事件退出。
- 大多数治疗中出现的不良事件为轻度(132起事件中110起[83.3%]),且与ACI-24疫苗无关或不太可能相关(132起事件中113起[85.6%])。
- 磁共振成像扫描未观察到伴水肿或脑微出血的淀粉样蛋白相关影像学异常,也无中枢神经系统炎症证据。
- 12名接受ACI-24的参与者中4名(33.3%)观察到抗Aβ免疫球蛋白G滴度升高(2名接受300μg、2名接受1000μg),安慰剂组0名;此外,接受ACI-24的个体血浆Aβ1-40和Aβ1-42水平升高幅度更大。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Individuals with Down syndrome (DS) are at high risk of developing Alzheimer disease due to an increased dose of the amyloid precursor protein gene, APP, which leads to increased levels of full-length APP and its products, including amyloid-β (Aβ). The liposome-based antiamyloid ACI-24 vaccine is intended to treat neurological disorders caused by misfolded Aβ pathological protein. However, the safety, tolerability, and immunogenicity of the ACI-24 vaccine among adults with DS have not been fully examined. OBJECTIVE: To assess the safety and tolerability of the ACI-24 vaccine among adults with DS as well as its ability to induce immunogenicity measured by anti-Aβ immunoglobulin G titers. DESIGN, SETTING, AND PARTICIPANTS: This multicenter double-blind placebo-controlled dose-escalation phase 1b randomized clinical trial was conducted at 3 US academic medical centers with affiliated Down syndrome clinics between March 30, 2016, and June 29, 2020. A total of 20 adults with DS were screened; of those, 16 adults were eligible to participate. Eligibility criteria included men or women aged 25 to 45 years with cytogenetic diagnosis of either trisomy 21 or complete unbalanced translocation of chromosome 21. Between April 27, 2016, and July 2, 2018, participants were randomized 3:1 into 2 dose-level cohorts (8 participants per cohort, with 6 participants receiving the ACI-24 vaccine and 2 receiving placebo) in a 96-week study. Participants received 48 weeks of treatment followed by an additional 48 weeks of safety follow-up. INTERVENTIONS: Participants were randomized to receive 7 subcutaneous injections of ACI-24, 300 μg or 1000 μg, or placebo. MAIN OUTCOMES AND MEASURES: Primary outcomes were measures of safety and tolerability as well as antibody titers. RESULTS: Among 16 enrolled participants, the mean (SD) age was 32.6 (4.4) years; 9 participants were women, and 7 were men. All participants were White, and 1 participant had Hispanic or Latino ethnicity. Treatment adherence was 100%. There were no cases of meningoencephalitis, death, or other serious adverse events (AEs) and no withdrawals as a result of AEs. Most treatment-emergent AEs were of mild intensity (110 of 132 events [83.3%]) and unrelated or unlikely to be related to the ACI-24 vaccine (113 of 132 events [85.6%]). No amyloid-related imaging abnormalities with edema or cerebral microhemorrhage and no evidence of central nervous system inflammation were observed on magnetic resonance imaging scans. Increases in anti-Aβ immunoglobulin G titers were observed in 4 of 12 participants (33.3%) receiving ACI-24 (2 receiving 300 μg and 2 receiving 1000 μg) compared with 0 participants receiving placebo. In addition, a greater increase was observed in plasma Aβ1-40 and Aβ1-42 levels among individuals receiving ACI-24. CONCLUSIONS AND RELEVANCE: In this study, the ACI-24 vaccine was safe and well tolerated in adults with DS. Evidence of immunogenicity along with pharmacodynamic and target engagement were observed, and anti-Aβ antibody titers were not associated with any adverse findings. These results support progression to clinical trials using an optimized formulation of the ACI-24 vaccine among individuals with DS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02738450.
引用
- Rafii MS, Sol O, Mobley WC, et al. Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial. JAMA Neurol. 2022. PMID: 35532913. doi:10.1001/jamaneurol.2022.0983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。